{"id":451761,"date":"2021-03-05T08:55:29","date_gmt":"2021-03-05T13:55:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451761"},"modified":"2021-03-05T08:55:29","modified_gmt":"2021-03-05T13:55:29","slug":"eisai-alzheimers-disease-pipeline-research-to-be-presented-at-virtual-ad-pd-2021-including-lecanemab-ban2401-data","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eisai-alzheimers-disease-pipeline-research-to-be-presented-at-virtual-ad-pd-2021-including-lecanemab-ban2401-data\/","title":{"rendered":"Eisai Alzheimer’s Disease Pipeline Research to be Presented at Virtual AD\/PD\u2122 2021, Including Lecanemab (BAN2401) Data"},"content":{"rendered":"
\n

– Oral presentations and posters highlighting Eisai’s investigational novel therapies and immunoassay system being studied for Alzheimer’s disease and its clinical symptoms<\/h2>\n

– Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation<\/h2>\n

– Virtual symposium: The Science Behind the A\u03b2 Pathway in Alzheimer’s Disease<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WOODCLIFF LAKE, N.J.<\/span>, March 5, 2021<\/span> \/PRNewswire\/ —\u00a0Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company’s robust Alzheimer’s disease (AD) pipeline, including lecanemab (BAN2401). Jointly developed by Eisai and Biogen Inc., lecanemab is an investigational humanized monoclonal antibody that binds to neutralize and eliminate soluble, toxic amyloid beta (A\u03b2) aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD. This data will be among Eisai’s many presentations at AD\/PD\u2122 2021 Virtual Conference, the 15th<\/sup> International Conference on Alzheimer’s and Parkinson’s Diseases, March 9 – 14, 2021<\/span>.<\/p>\n

\n

\n
\n \"Eisai
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Alzheimer’s disease is a progressively debilitating and devastating neurodegenerative disease. The focus on Alzheimer’s disease has historically been on alleviating cognitive and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease through the science of biomarkers. We look forward to sharing data and discussing the scientific rationale that the amyloid beta pathway plays a key role in the pathophysiology of Alzheimer’s disease,” said Harald\u00a0Hampel, M.D., Ph.D., Vice President, Chief Medical Officer, Neurology Business Group, Eisai Inc., who was recently named one of the world’s top five Alzheimer’s disease experts by Expertscape based on objective ranking of his contribution and impact on the Alzheimer’s field through scientific publications.\u00a0<\/p>\n

\n Eisai and Biogen Joint Investigational Assets<\/b>\n <\/p>\n

Eisai Oral Presentation for Lecanemab:<\/p>\n